Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02786901 · ClinicalTrials.gov registry record · Phase 3
LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
NCT02786901 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 600 participants.
The verdict
NCT02786901, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
Study Summary
Loteprednol Etabonate Ophthalmic Gel, (BID and TID) versus Vehicle Group for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery.
Interventions
- DRUG Vehicle Gel
- DRUG Loteprednol Etabonate Ophthalmic Gel dosed TID
- DRUG Loteprednol Etabonate Ophthalmic Gel dosed BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2016-06 |
| Est. Completion | 2017-07-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02786901
The ClinicalTrials.gov registry entry for NCT02786901 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vehicle Gel is the first listed.
NCT02786901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02786901 about?
NCT02786901 is a clinical study titled "LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery". Loteprednol Etabonate Ophthalmic Gel, (BID and TID) versus Vehicle Group for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery.
What is the current status of trial NCT02786901?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2016-06. Estimated completion is 2017-07-01.
What interventions are being tested in trial NCT02786901?
The interventions under investigation include: Vehicle Gel (DRUG), Loteprednol Etabonate Ophthalmic Gel dosed TID (DRUG), Loteprednol Etabonate Ophthalmic Gel dosed BID (DRUG).
Who is sponsoring clinical trial NCT02786901?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.